MedX Health Corp. Announces Regulatory Clearance for its SIAscopy Medical Devices in New Zealand

2/28/18: MedX Health Corp. (“MedX”) (TSX-V: MDX) announced today it has received regulatory clearance from the New Zealand Medicines and Medical Devices safety authority (Medsafe WAND) to sell its SIAscope medical device in New Zealand.
Share the News

MedX Health states New Zealand has the highest rate of melanoma skin cancer in the world – eclipsing Australia as the most dangerous place to be exposed to the sun, according to new research published in the Journal of Investigative Dermatology. “MedX believes it can greatly reduce the incidence of skin cancer mortality through early detection and is committed to entering markets that have a high incidence of skin cancer to address this life-threatening issue,” said Rob von der Porten, President & CEO.

“MedX will develop the New Zealand market by establishing a strong, local partner to distribute our rapid skin assessment technology, as we have done in other international markets. Our experience is that securing a partner with local market knowledge and relationships is key to entering and growing our sales in that market,” added Mr. von der Porten.